<seo title="Moderna" metakeywords="developing commercializing mrna,development commercialization mrna,moderna biotechnology company,commercializing mrna based" metadescription="Moderna is a biotechnology company that is focused on developing and commercializing messenger RNA (mRNA) therapeutics and vaccines."/>
===Introduction to Moderna===

Moderna is a biotechnology company that is focused on developing and commercializing messenger RNA (mRNA) therapeutics and vaccines. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna is a publicly traded company on the Nasdaq stock exchange and has a [[Market Capitalization|market capitalization]] of over $50 billion. Moderna has developed a platform technology that enables the development of mRNA-based therapeutics and vaccines for a wide range of diseases. The company has a broad pipeline of mRNA-based therapeutics and vaccines in development for a variety of indications, including cancer, infectious diseases, and rare diseases.
===History of Moderna===

Moderna was founded in 2010 by Flagship Pioneering, a [[Venture Capital|venture capital]] firm based in Cambridge, Massachusetts. The company was initially focused on developing mRNA-based therapeutics and vaccines for cancer. In 2013, Moderna raised $450 million in a [[Series B Financing|Series B financing]] round, which was the largest venture capital financing round in the history of biotechnology. Since then, the company has raised additional capital and has expanded its focus to include a broad range of diseases.
===Moderna’s Business Model===

Moderna’s business model is focused on the development and commercialization of mRNA-based therapeutics and vaccines. The company has a broad pipeline of mRNA-based therapeutics and vaccines in development for a variety of indications, including cancer, infectious diseases, and rare diseases. Moderna has established partnerships with a number of pharmaceutical companies, including Merck, AstraZeneca, and Sanofi, to develop and commercialize its mRNA-based therapeutics and vaccines.
===Moderna’s Financial Performance===

Moderna has experienced significant growth in recent years. The company’s revenue has grown from $1.2 million in 2016 to $1.7 billion in 2020. Moderna’s [[Net Income|net income]] has also grown significantly, from a loss of $1.2 billion in 2016 to a profit of $1.2 billion in 2020. The company’s stock price has also increased significantly, from $14.50 per share in 2016 to $150.00 per share in 2021.
===Moderna’s Future Outlook===

Moderna’s future outlook is positive. The company is well-positioned to capitalize on the growing demand for mRNA-based therapeutics and vaccines. Moderna has a broad pipeline of mRNA-based therapeutics and vaccines in development for a variety of indications, and the company has established partnerships with a number of pharmaceutical companies to develop and commercialize its products. In addition, the company has a strong [[Balance Sheet|balance sheet]] and is well-positioned to continue to grow and expand its business.
===Conclusion===

Moderna is a biotechnology company that is focused on developing and commercializing mRNA-based therapeutics and vaccines. The company has experienced significant growth in recent years and has a strong balance sheet. Moderna has a broad pipeline of mRNA-based therapeutics and vaccines in de